The FDA Paused Biohaven’s Pivotal Epilepsy Enrollment Two Weeks After Its Up to $795M SK Deal as an Artisan Manager Demanded Novartis Board Changes: The Surrogate Discount Tally (September 11, 2026)

Last updated: September 11, 2026

The FDA paused new enrollment in Biohaven’s pivotal opakalim epilepsy trials on September 10 over a rodent metabolite finding, fifteen days after SK Biopharmaceuticals licensed the drug for up to $795 million. The same day, an Artisan Partners manager publicly demanded Novartis board changes.

This page covers the Biohaven partial clinical hold and what it does to the SK deal math, the investor call for a Novartis board shake up, the full closing tally of the surrogate discount week, Axogen’s $200 million BioCircuit acquisition, Frazier’s new $1.1 billion public fund, and the dated catalysts ahead.

What exactly did the FDA do to Biohaven’s opakalim program?

The agency placed a partial clinical hold that stops new patient enrollment in the pivotal focal epilepsy program for opakalim, also called BHV-7000. Patients already randomized keep receiving the drug. The company disclosed the hold in a regulatory filing on September 10, and shares closed down 14.7 percent.

Opakalim is a Kv7 potassium channel activator, a mechanism that damps neuronal excitability without the sedation burden of older antiseizure drugs. The hold traces to a metabolite, a drug related substance, that turned up in rodent studies. The FDA wants additional nonclinical data before new patients enroll. Biohaven’s position, per its statement carried by BioSpace and BioPharma Dive, is that the findings “may be specific to rodents and not relevant to human safety.” The company must complete further nonclinical work to make that case.

The practical impact splits cleanly across the two pivotal trials:

Together the two studies span more than 600 participants, per BioSpace. Because RISE 3 finished enrolling in June, the hold does not touch the near term value driver: William Blair’s Myles Minter, quoted by BioPharma Dive, still calls the RISE 3 topline a key event for the company this year. What the hold does hit is the second pivotal, the one a regulatory filing would likely want alongside the first.

Does the hold change the SK Biopharmaceuticals deal?

Not on paper. On August 26, SK Biopharmaceuticals licensed Biohaven’s entire Kv7 platform, opakalim included, for up to $795 million with $350 million upfront. Analyst commentary carried by BioPharma Dive noted Biohaven disclosed all clinical and nonclinical data before signing, metabolite information included, meaning SK bought with eyes open.

That detail cuts both ways. It means the deal is unlikely to unwind on a disclosure dispute, and it means a sophisticated buyer looked at the metabolite package and still wrote the check. But it also means the market’s read of the August deal as a de risking event was premature by exactly fifteen days. Biohaven came into September carrying a 2025 that included a Phase 2 depression miss for the same molecule and an FDA rejection of its spinocerebellar ataxia drug, followed by a 60 percent R&D budget cut. The Kv7 license was the balance sheet repair story. A regulator pausing enrollment in the flagship indication two weeks later is the kind of sequence this market has punished all month, and it did: the stock lost 14.7 percent in a session.

For the running theme of this week, note the shape: a topline or a deal gets announced without the underlying document, the market reprices it as fact, and the document, or the regulator, arrives later with the complication. We covered the same dynamic in Thursday’s arlo-cel and Hyrnuo coverage.

Why is an Artisan Partners manager calling for Novartis board changes?

David Samra, a managing director at Artisan Partners, which Reuters describes as a top 20 Novartis shareholder, urged chairman Giovanni Caforio to strengthen board oversight of dealmaking after a string of expensive clinical failures. His words, as reported by Reuters and carried by Fierce Pharma: the results have been “uninspiring at best,” and the changes need to happen at the board level.

The ledger behind the complaint, with attribution where no primary document exists:

Novartis defended its capital allocation as disciplined and shareholder friendly and left sales guidance unchanged for the periods before and after 2030. The stock closed unchanged at $137.48, which after a 14.1 percent week reads less like calm than exhaustion. Our arithmetic on official exchange closes: $159.99 on September 4 to $137.48 on September 10.

The governance angle matters beyond Basel. This is the first time in the current repricing cycle that a major institutional holder has converted a surrogate endpoint failure into a formal demand about who sits on a board. Boards across the sector that approved biomarker driven acquisitions at premium prices now have a live precedent for what happens when the confirmatory data misses.

What did the surrogate discount week actually cost?

The week that began with pelacarsen’s failure and ran through three numberless toplines and two surrogate based approvals ended with every name in the Lp(a) and readacross cohort lower. Official exchange closes, Friday September 4 to Thursday September 10; percentages are our arithmetic on those closes:

Two observations belong in the record. First, Amgen’s slide did not stop when the readacross argument was fully priced; the stock fell a further 2.2 percent Thursday with no new disclosure we could find, and the first scheduled venue for management to address the olpasiran question is now dated: Amgen presents at the Morgan Stanley Global Healthcare Conference on Tuesday, September 15 at 11:30 am ET, per the company’s own notice. Second, none of the week’s four undated data IOUs, the Lp(a)HORIZON full dataset, del-desiran’s HARBOR data, DeLLphi-305, and arlo-cel’s QUINTESSENTIAL, acquired a congress date by Thursday night. The only withheld number in the whole complex with a due date attached remains Boston Scientific’s October 28 guidance revision.

What did Axogen buy for $200 million?

Axogen agreed to acquire BioCircuit Technologies for $200 million in cash at closing, with $1.0 million withheld pending a post closing adjustment, per the company’s September 10 release. The prize is NerveTape, which the release calls the first FDA approved device for sutureless peripheral nerve repair.

NerveTape lets surgeons align, connect, and protect transected nerves without microsuturing, a specialized technique that limits which surgeons can perform nerve repair at all. Axogen plans to push the device through its existing commercial infrastructure, surgeon relationships, and hospital contracts. BioCircuit’s electronics research business spins out before the deal closes, expected in the fourth quarter of 2026. Axogen calls the deal accretive to revenue growth, adjusted EBITDA margin, and adjusted earnings per share in the first year after close, with 2027 guidance coming in the first quarter.

The market’s objection was the funding, not the strategy: the acquisition rides on a public equity offering announced the same day, which MedTech Dive reports is expected to raise about $208.7 million. AXGN closed at $41.85, down 11.5 percent on the dilution.

Who is funding biotech right now?

The capital markets barbell we have tracked since August got heavier on both ends. Frazier Life Sciences closed a $1.1 billion raise for its Frazier Life Sciences Public Fund, per the firm’s announcement reported by Fierce Biotech, bringing the vehicle to $2.8 billion raised since its 2021 launch. The fund buys long term positions in small and mid cap public biotechs and participates in late stage private crossover rounds. Managing partner Albert Cha pointed to clinical, regulatory, and commercial momentum across the sector.

The same day, BioSpace’s job trends desk counted August biopharma layoffs at just over 500 people, down 90 percent year over year, a striking normalization after two brutal years. Massachusetts Governor Maura Healey, meeting industry leaders, still described biotech capital as harder to come by, which is true at the preclinical end even as a billion dollar public markets fund closes and ADARx’s IPO, filed September 4, waits to price alongside Oura’s.

Set against Tuesday’s $550 million private financing day, the shape of the market is consistent: capital is abundant for late stage, de risked, or public stories and scarce for everything earlier. That is the same barbell, and it is getting more pronounced.

What else moved on September 10?

Takeda: Andy Plump, R&D chief since joining from Sanofi in 2015, will retire and stays on until a successor is appointed, per Fierce Biotech. His tenure spans the approvals of Orzeyful and Mimrylo last month, positive Phase 3 zasocitinib data, and earlier approvals of Livtencity, Adzynma, and Eohilia, along with the cell therapy exit and the Alofisel Phase 3 failure. TAK ADRs closed at $18.11.

CDMO capacity: Lonza announced a commercial scale spray drying facility addition at its Bend, Oregon site, extending the US onshoring wave in drug product manufacturing. Endpoints News separately reported Samsung Biologics signed a $262 million manufacturing contract; the client was not named in the reporting we could verify.

Clinical misses: Shionogi’s stroke candidate failed a mid stage trial, per Endpoints. Tyra Biosciences shares slipped after bladder cancer response data came in below investor expectations, per BioSpace. BridgeBio Oncology narrowed the scope of its KRAS program, per Endpoints.

Policy: An industry survey described the most favored nation pricing environment as a policy earthquake forcing drugmakers to cherry pick launch regions, per BioSpace and Fierce Pharma coverage. The FDA separately signaled regulatory flexibility for psychedelic assessment, per Endpoints, relevant to Definium’s Panorama generalized anxiety topline due this month. Heidi Overton’s confirmation hearing remains unscheduled as of Thursday night.

Which catalysts are next on the calendar?

The near term dated slate, updated through September 10:

Frequently asked questions

What is a partial clinical hold?

A partial clinical hold is an FDA order that stops part of a clinical program, here new patient enrollment, while allowing the rest to continue, here dosing of already enrolled patients. A full hold stops everything. Partial holds resolve when the sponsor answers the agency’s specific question.

Which Biohaven trials are affected by the hold?

RISE 2, which was still recruiting, cannot enroll new patients. RISE 3, fully enrolled since June 2026, continues without restriction, and its topline is still expected in 2026. Dosing continues for every patient already randomized in both studies.

Why did the FDA pause opakalim enrollment?

Rodent studies identified a metabolite, a substance the body produces when processing the drug, that the agency wants characterized with additional nonclinical data. Biohaven says the finding may be specific to rodents and not relevant to human safety, but it must generate data to show that.

Does the hold affect the SK Biopharmaceuticals licensing deal?

The deal stands. SK licensed the Kv7 platform on August 26 for up to $795 million with $350 million upfront, and reporting indicates SK reviewed all data, including metabolite findings, before signing. Whether the hold changes milestone timing has not been disclosed.

What is opakalim’s mechanism of action?

Opakalim, or BHV-7000, activates Kv7 potassium channels, which stabilizes overexcitable neurons and suppresses seizure activity. The mechanism aims at efficacy without the sedation and cognitive burden of many existing antiseizure medicines, which is central to its commercial thesis in focal epilepsy.

Who is demanding changes at Novartis and why?

David Samra, a managing director at Artisan Partners, which Reuters describes as a top 20 Novartis shareholder. He wants chairman Giovanni Caforio to strengthen board level oversight of dealmaking after the del-desiran, pelacarsen, and pelabresib setbacks, calling the record uninspiring at best.

How much has Novartis stock fallen this week?

Novartis ADRs fell from $159.99 on September 4 to $137.48 on September 10, a decline of 14.1 percent by our arithmetic on official exchange closes, spanning the pelacarsen outcomes failure and the del-desiran Phase 3 miss.

Did Amgen’s stock recover after the Lp(a) readacross selloff?

No. AMGN closed at $382.47 on September 10, down 12.5 percent for the week and down a further 2.2 percent on Thursday alone with no new company disclosure. Amgen’s September 15 Morgan Stanley conference appearance is the first scheduled venue for management commentary.

What did Axogen agree to acquire?

Axogen agreed to buy BioCircuit Technologies for $200 million in cash at closing, funded by a concurrent equity offering. BioCircuit makes NerveTape, the first FDA approved device for sutureless peripheral nerve repair. The deal is expected to close in the fourth quarter of 2026.

What is NerveTape and why does it matter?

NerveTape is a device that lets surgeons connect severed peripheral nerves without microsutures. Because microsuturing is a specialized skill, a sutureless option can expand which surgeons and sites perform nerve repair, which is the volume argument behind Axogen’s $200 million price.

What is the Frazier Life Sciences Public Fund?

A $1.1 billion vehicle from Frazier Life Sciences, announced September 10, that takes long term positions in small and mid cap public biotech companies and joins late stage private crossover financings. The fund has raised $2.8 billion in total since launching in 2021.

When is the anito-cel FDA decision?

December 23, 2026. Gilead’s February acquisition release states the anitocabtagene autoleucel BLA was accepted with that anticipated PDUFA action date in fourth line multiple myeloma. That decision is the external clock against which BMS must place its arlo-cel data and filing.

Is Takeda’s R&D chief leaving?

Yes. Andy Plump, chief of R&D since arriving from Sanofi in 2015, will retire and remains in the role until Takeda names a successor. Recent approvals under his tenure include Orzeyful and Mimrylo, both cleared last month.

What happens to Amylyx’s unclosed offering?

The $500.2 million offering priced August 19 at $35.50 per share has not been declared closed, and AMLX has now finished below the offer price nine consecutive sessions, closing at $32.09 on September 10. Standard greenshoe mechanics force disclosure by roughly September 18.

Sources

Primary sources: Biohaven regulatory disclosure of the partial clinical hold as reported September 10; SK Biopharmaceuticals and Biohaven licensing announcement, August 26, 2026; Axogen acquisition press release, September 10, 2026 (GlobeNewswire); Gilead Sciences acquisition release stating the anito-cel PDUFA date, February 23, 2026; Amgen conference participation notice, September 9, 2026 (PRNewswire); Frazier Life Sciences fund announcement via Business Wire, September 10, 2026; official exchange closing prices, September 4 through 10, 2026 (market data; percentage moves are our arithmetic; moves without a company disclosure carry no cause assigned).

Trade coverage (September 10, 2026 unless noted): BioSpace (Biohaven hold; Tyra; August layoff count; MFN survey coverage); BioPharma Dive (Biohaven hold detail and analyst commentary); Endpoints News (Biohaven; Shionogi; BridgeBio Oncology; Lonza and Samsung Biologics; FDA psychedelics flexibility); Fierce Pharma via Reuters (Artisan Partners and Novartis); Fierce Biotech (Frazier fund; Takeda; Massachusetts); MedTech Dive (Axogen financing detail).

Related coverage

• BMS’ arlo-cel pivotal win with the numbers withheld, Hyrnuo’s first line approval, and the $550M financing day
• Novartis’ $12B Avidity bet missed in Phase 3 as Amgen fell 10.1% on Lp(a) readacross
• Pelacarsen’s 8,323 patient Lp(a) outcomes failure, where the surrogate discount week began
• Biohaven’s up to $795M Kv7 licensing deal with SK, covered at signing
• The autoimmune CAR T pauses, the sector’s other live FDA hold thread
• The binary ledger reference table